Suche klinische Studie
Weitere Suchoptionen
94 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Abgeschlossene Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STRONGTREAT: Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis - ES (Completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Prospektive, randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Phase III-Studie zur Einschätzung der klinischen Wirksamkeit und Sicherheit des polyclonalen Anti- Pseudomonas-Antikörpers IgY zur Vermeidung des Wiederauftretens einer Pseudomonas Aeruginosa-Infektion bei Patienten mit zystischer Fibrose
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors (PRECARDIA)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis (Phase II) - ES (Completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNy) Monoclonal Antibody, in Paediatric Patients with Primary Haemophagocytic Lymphohistiocytosis which has Reactivated - ES (terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of BMN 045 (previously known as PRO045) in subjects with Duchenne muscular dystrophy - UK (Terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - UK
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - SK
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase I/II, non randomized, multicenter, open-label study of G1XCGD (lentiviral vector transduced CD34+ cells) in patients with X-Linked Chronic Granulomatous Disease - UK
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody - ES (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MABSOT: A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function - UK
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy - BE (Terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine offene, einarmige, multizentrische Pilot-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit der mehrfach intravenöser Gabe von NI-0501, einem monoklonalen Anti-Interferon-Gamma (Anti-IFNy) Antikörper, bei pädiatrischen Patienten mit reaktivierter primären hämophagozytischen Lymphohistiozytose (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function - ES (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine Phase II-Studie des tumorspezifischen menschlichen Fusionsproteins monoklonalen Zytokin-Antikörpers F16IL2 in Kombination mit Paclitaxel versus Paclitaxel allein bei Patienten mit metastatischem Merkelzellkarzinom - DE -completed-
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Study of the safety and preliminar effectiveness of infused allogeneic mesenchymal stem cells (MSC) derived from adipose tissue in patients with Recessive Dystrophic Epidermolysis Bullosa (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Pilot, Open-label, Single Arm, Multicentre Study to Explore Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNgamma) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis- IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NEUROSIS « Neonatal European Study of Inhaled Steroids »: Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia - Phase III - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNgamma) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody (Phase II) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
INTEREST study: A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Syndrome - ES (terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DietINT: A Randomized Phase II Study for Tertiary Prevention of Squamocellular Cancer of Head and Neck (SCCHN) With a Dietary Intervention - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
LENA-WP08: Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase I/II G1XCGD.01 Sudie: Nicht randomisierte, multizentrische, offene Phase I/II-Gentherapiestudie mit g1xcgd (Lentiviral Vector Transduced cd34+ Cells) zur Behandlung der X-chromosomalen chronischen Granulomatose
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MesaCapp: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (Phase 2) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) - US
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis- BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-Label, Langzeit-Follow-up der Sicherheit und biochemischen Krankheitskontrolle von Infacort® bei Neugeborenen, Säuglingen und Kindern mit angeborener Nebennierenhyperplasie und Nebenniereninsuffizienz, die zuvor in die Infacort 003-Studie aufgenommen wurden
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
JIKI: Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Offene, langfristige Extensionsbehandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der IEDAT-02-2015-Studie teilgenommen haben -DE-
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia (Phase III) - ES (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - ES
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) - IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis - IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)- BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea (Ebola-Tx) (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DENIM: A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy- BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Subjects Affected by Acanthamoeba Keratitis - PL
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MIROCALS : Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DENIM : A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomisierte, doppelblinde, Placebo-kontrollierte, Dosis-Eskalationsstudie zur Beurteilung der Sicherheit, Verträglichkeit und Pharmakokinetik von QR-010 bei CF-Patienten mit homozygoter deltaF508-Mutation
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
The "DeSScipher" Project - to Decipher the Best Treatment for Systemic Sclerosis - Observational Trial 2: Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis- BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the delta F508 CFTR Mutation (Phase I) - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis- FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis - GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine explorative klinische Studie von Patienten in der frühen Phase der Huntington-Krankheit zur Beurteilung der Pharmakokinetik, der pharmakodynamischen Messungen des Zieleingriffs und der Krankheitsmodulation sowie der akuten phänotypischen Effekte nach mehreren oralen Dosen von SEN0014196
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized controlled trial (RCT) to determine the efficacy and safety of azithromycin (AZN) maintenance therapy for 6 months in subjects with PCD - A double-blind, parallel group study - GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GANNET53: A Two-part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination With Paclitaxel Weekly in Women With High-grade Serous, High-grade Endometrioid, or Undifferentiated, Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomisierte kontrollierte Studie (RCT) zur Bestimmung der Wirksamkeit und Sicherheit der Erhaltungstherapie mit Azithromycin (AZN) für 6 Monate bei Patienten mit PCD - Eine doppelblinde, parallele Gruppenstudie.
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: A phase I/II trial of IMA970A plus CV8102 following a single pre-vaccination infusion of cyclophosphamide in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments - ES (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments - GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: A phase I/II trial of IMA970A plus CV8102 following a single pre-vaccination infusion of cyclophosphamide in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUDARIO: A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment with Niraparib versus Ganetespib plus Carboplatin in platinum-sensitive ovarian cancer patients - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HCQ-chILD-EU: Hydroxychloroquine in pediatric ILD - START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and safety of hydroxychloroquine (HCQ) - ES (terminated)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis- IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - IE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: Eine Phase-I/II-Studie mit IMA970A plus CV8102 nach einer einzigen Präimpf-Infusion von Cyclophosphamid bei Patienten mit einem sehr frühen, frühen und mittleren Stadium des hepatozellulären Karzinoms nach allen Standardbehandlungen
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GLIOMARK1: Exploratorische Phase II-Studie bei Patienten nach Behandlung eines hochgradigen Hirntumors zur Beurteilung des Stellenwerts von Tc-99m Tetrofosmin bei der Differenzierung zwischen Rezidiv und Strahlennekrose
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Treg Therapy: Therapie der Steroid-refraktären chronischen Graft-versus-Host-Erkrankung mit regulatorischen Spender-T-Zellen
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma-GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia-GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children-GB
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NISCI: Antibodies Against Nogo-A to Enhance Plasticity, Regeneration and Functional Recovery After Spinal Cord Injury - A Multicenter International Randomized Double Blind Placebo Controlled Phase II Clinical Proof of Concept Trial - CH
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (Phase 1)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
ENALONG: Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
LENA-WP09: Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapie: Eine offene Phase I/IIa-Studie zur Wiederverwendung von Carbamazepin (CBZ) für die Behandlung von Skelettdysplasien bei Kindern
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: Internationale randomisierte kontrollierte Studie zur Chemotherapie für die Behandlung von rezidivierenden und primären refraktären Ewing-Sarkomen
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Offene, langfristige, verlängerte Behandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der Studie IEDAT-02-2015 teilgenommen haben
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUDARIO: A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin [...] in Platinum-sensitive Ovarian Cancer Patients - FR
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PHITT: Paediatric Hepatic International Tumour Trial (Phase 3) - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TUDCA-ALS: Sicherheit und Wirksamkeit von TUDCA als Zusatztherapie bei ALS-Patienten
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase I/II Double-blind, Randomized, Placebo Controlled, Safety and Immunogenicity, Dose-finding Trial of the Monovalent Zaire Ebola Chimpanzee Adenovirus Vector Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) - ES (completed)
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: Eine internationale, multizentrische, randomisierte, kontrollierte Phase III-Studie zur Evaluation von Mirtazapin zur Linderung von Atemnot in Palliative Care
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CARAMBA-1 : Eine klinische Studie der Phase I/IIa zur Beurteilung der Durchführbarkeit, Sicherheit und Antitumoraktivität von autologen SLAMF7 CAR-T-Zellen beim Multiplen Myelom
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROSHOCK: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock - AT
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROSHOCK: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock - ES
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CARAMBA-1: A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma - ES
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients - BE
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STOPFOP: Saracatinib-Studie zur Vorbeugung von FOP. Eine 6-monatige randomisierte, kontrollierte Doppelblindstudie mit AZD0530 im Vergleich zu Placebo, gefolgt von einer 12-monatigen Open-Label-Verlängerungsphase
European Commission
DG Research - Directorate General for Research
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS